达安基因
(002030)
| 流通市值：92.07亿 | | | 总市值：92.07亿 |
| 流通股本：14.03亿 | | | 总股本：14.03亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 338,574,032.79 | 169,136,638.98 | 853,024,340.06 | 591,050,057.91 |
| 营业收入 | 338,574,032.79 | 169,136,638.98 | 853,024,340.06 | 591,050,057.91 |
| 二、营业总成本 | 488,712,041.64 | 238,175,840.05 | 1,058,064,537.31 | 695,779,975.01 |
| 营业成本 | 226,711,221.69 | 116,639,813.97 | 532,743,357.51 | 354,750,208.8 |
| 税金及附加 | 2,529,942.09 | 957,379.27 | 9,533,974.98 | 4,212,451.3 |
| 销售费用 | 107,190,777.47 | 45,354,577.5 | 208,135,259.78 | 105,810,189.55 |
| 管理费用 | 67,054,419.39 | 31,562,428.43 | 147,052,511.51 | 111,681,235.85 |
| 研发费用 | 104,696,043.57 | 53,947,875.38 | 225,668,337.11 | 167,134,295.16 |
| 财务费用 | -19,470,362.57 | -10,286,234.5 | -65,068,903.58 | -47,808,405.65 |
| 其中:利息费用 | 2,100,374.22 | 1,220,515.45 | 9,744,538.33 | 5,742,298.28 |
| 其中:利息收入 | 26,033,375.07 | 13,156,077.19 | 69,372,365.34 | 53,386,221.47 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 85,568,280.89 | 200,727,294.7 | -175,745,759.4 | -119,224,149.48 |
| 加:投资收益 | 4,777,877.08 | -24,752,707.19 | -253,838,060.16 | -130,108,689.2 |
| 资产处置收益 | 476,575.74 | 4,911.43 | 9,096,715.23 | 2,077,739.9 |
| 资产减值损失(新) | -5,828,434.13 | -3,490,664.44 | -75,039,742.89 | -113,954.43 |
| 信用减值损失(新) | -171,131,831.27 | -22,202,238.09 | -407,831,786.93 | -247,295,765.62 |
| 其他收益 | 19,908,076.46 | 11,929,429.77 | 40,793,337.41 | 32,632,643.94 |
| 四、营业利润 | -216,367,464.08 | 93,176,825.11 | -1,067,605,493.99 | -566,762,091.99 |
| 加:营业外收入 | 1,534,695.23 | 793,129.91 | 2,584,173.89 | 436,836.52 |
| 减:营业外支出 | 4,350,805.79 | 140,725.39 | 6,142,074.3 | 1,552,357.49 |
| 五、利润总额 | -219,183,574.64 | 93,829,229.63 | -1,071,163,394.4 | -567,877,612.96 |
| 减:所得税费用 | -29,058,942.1 | 42,566,394.4 | -132,050,533.38 | -66,376,049.48 |
| 六、净利润 | -190,124,632.54 | 51,262,835.23 | -939,112,861.02 | -501,501,563.48 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -190,124,632.54 | 51,262,835.23 | -939,112,861.02 | -501,501,563.48 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -182,160,988.3 | 52,924,282 | -925,169,864.75 | -502,719,727.25 |
| 少数股东损益 | -7,963,644.24 | -1,661,446.77 | -13,942,996.27 | 1,218,163.77 |
| 扣除非经常损益后的净利润 | -264,517,382.29 | -98,960,664.05 | -822,653,095.84 | -432,847,055.74 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.13 | 0.04 | -0.66 | -0.36 |
| (二)稀释每股收益 | -0.13 | 0.04 | -0.66 | -0.36 |
| 八、其他综合收益 | -691,778.51 | -38,440.51 | -3,309,277.01 | 125,820.15 |
| 归属于母公司股东的其他综合收益 | -597,420.11 | -22,401.25 | -3,491,876.88 | 162,725.34 |
| 九、综合收益总额 | -190,816,411.05 | 51,224,394.72 | -942,422,138.03 | -501,375,743.33 |
| 归属于母公司股东的综合收益总额 | -182,758,408.41 | 52,901,880.75 | -928,661,741.63 | -502,557,001.91 |
| 归属于少数股东的综合收益总额 | -8,058,002.64 | -1,677,486.03 | -13,760,396.4 | 1,181,258.58 |
| 公告日期 | 2025-08-30 | 2025-04-30 | 2025-03-29 | 2024-10-31 |
| 审计意见(境内) | | | 标准无保留意见 | |